Five-Year ASCOT Follow-Up Extends the Survival Case for Adjuvant S-1 in Biliary Tract Cancer
The final prespecified follow-up from ASCOT strengthens the argument for S-1 after curative-intent surgery for biliary tract cancer. In this phase III Japanese trial, the oral fluoropyrimidine maintained a survival advantage well beyond the original 3-year analysis, with a median follow-up of 61.5 months showing a 5-year overall survival of 64% in the S-1 arm versus 52% with observation. The hazard ratio for death was 0.72, with a one-sided P value of .01.
The signal did not fade with time. It held.
That matters in biliary tract cancer, a disease in which microscopic residual disease and early systemic spread often decide outcomes even after apparently complete resection. Surgery can remove the visible tumor burden, but the biologic problem frequently persists at the cellular level. A postoperative agent with activity against occult disease therefore fits the underlying pattern of failure in this malignancy, where recurrence remains common despite technically successful operations.
Survival Separation Deepened Over Long-Term Follow-Up
ASCOT enrolled 440 patients with resected biliary tract cancer and randomized them to observation or adjuvant S-1. The treatment schedule used here was practical and oral: 40 mg/m2 twice daily for 4 weeks on and 2 weeks off, given for four cycles. In the intention-to-treat population, the median overall survival reached 8.2 years with S-1 and 5.9 years with observation. The trial’s original 3-year survival improvement now appears less like a short-lived fluctuation and more like a durable treatment effect.
The long tail of the Kaplan-Meier curve is clinically meaningful. Patients with biliary tract cancer who remain alive years after surgery are not merely statistical survivors; they are often the individuals in whom adjuvant therapy has delayed or prevented recurrence long enough for cure to become a realistic possibility. In a disease where relapse can occur silently and rapidly, extending survival by years rather than months changes the clinical conversation in the postoperative clinic.
Relapse-Free Survival Did Not Mirror Overall Survival Cleanly
The relapse-free survival readout was less straightforward. Median relapse-free survival was 3.5 years in the observation group and 6.1 years in the S-1 group, but the report presents this comparison in a way that requires attention to directionality: the hazard ratios listed were 0.80 for the unstratified analysis and 0.76 for the stratified analysis, with the latter crossing into statistical significance. Even so, the overall message is clear enough for practice: adjuvant S-1 did more than postpone death; it also delayed recurrence in a meaningful subset of patients.
This pattern is biologically plausible. Fluoropyrimidines exert antimetabolic pressure on rapidly dividing cells, and in the postoperative setting that activity is aimed at occult micrometastatic disease. In biliary tract cancer, where relapse may be seeded before surgery and remain below the threshold of imaging detection, suppressing those invisible clones can translate into delayed recurrence and improved long-term survival. The benefit is not dependent on dramatic tumor shrinkage; it depends on preventing regrowth after the primary lesion has already been removed.
Subgroup Consistency Supports a Broad Postoperative Role
Treatment effects were generally consistent across subgroups, which gives the trial added weight in a setting where pathologic heterogeneity is the rule rather than the exception. Biliary tract cancer is not one disease but several related entities, and postoperative decision-making is often complicated by tumor site and nodal status. A benefit that persists across these clinical divisions is more useful than one limited to a narrow slice of patients.
The trial was also multicenter and open-label, a design that reflects real-world postoperative care in Japan while still preserving randomized comparison. Open-label treatment can introduce expectation bias in symptom reporting and care patterns, but overall survival is a hard endpoint that resists subjective drift. Death cannot be blunted by optimism.
Why the Final Analysis Matters for Practice
The prespecified final 5-year analysis is more than a confirmatory update. It closes the loop on whether the earlier 3-year survival gain represented an early signal or a durable therapeutic effect. The answer now appears settled: adjuvant S-1 continues to separate from observation over time, with a clinically important difference in overall survival and a favorable direction in relapse-free survival.
For surgeons and medical oncologists managing resected biliary tract cancer, that has immediate implications. A postoperative oral regimen that improves long-term survival is especially valuable in a disease where many patients are recovering from major hepatobiliary surgery and may not tolerate more intensive systemic approaches. Oral therapy also reduces some of the logistical barriers that can limit postoperative treatment delivery, although adherence and tolerability still require close attention in everyday practice.
The durability of benefit also argues against viewing adjuvant therapy as a short bridge after surgery. In biliary tract cancer, the postoperative period is not just a recovery phase; it is a therapeutic window in which residual disease can still be influenced. S-1 appears capable of shifting that window in favor of the patient.
Five-Year Data Reinforce S-1 as a Standard Option
With a 5-year overall survival of 64% versus 52%, a hazard ratio of 0.72, and a median survival difference of more than two years, ASCOT now offers a coherent long-term case for adjuvant S-1 after resection for biliary tract cancer. The findings align with the earlier 3-year analysis and extend them into a period where recurrences, deaths, and durable remissions become easier to distinguish from transient post-treatment noise.
The study still leaves practical questions at the bedside. Which pathologic subgroups benefit most? How does S-1 compare directly with other adjuvant approaches outside Japan? What is the optimal integration with evolving perioperative strategies? Those questions remain important, but they sit downstream from a larger point now supported by five-year follow-up: adjuvant S-1 can change the survival trajectory after resection for biliary tract cancer, and the effect persists long enough to matter to patients and clinicians alike.